diabetes

#NephMadness 2020: Thinking Outside The Paint – SGLT2 Inhibitors for Patients Without Diabetes Mellitus?

April 29, 2020 // 0 Comments

Brendon Neuen @brendonneuen Brendon Neuen is an academic nephrology registrar at Royal North Shore Hospital and an NHMRC Postgraduate Scholar at The George Institute in Sydney, Australia. His research focuses on the effects of SGLT2 inhibitors on [read more...]

#NephMadness 2020: SGLT2i Region

March 13, 2020 // 2 Comments

Submit your picks! | NephMadness 2020 | #NephMadness | #SGLT2iRegion Selection Committee Member: Meg Jardine @jardine_meg Meg Jardine is Program Head of Innovation & Kidney Research at The George Institute, Head of Renal Trials at George [read more...]

#NephMadness 2020: Hyperkalemia Region

March 13, 2020 // 0 Comments

Submit your picks! | NephMadness 2020 | #NephMadness | #HyperKRegion Selection Committee Member: Deborah Clegg Deborah Clegg is Associate Dean of Research in the College of Nursing and Health Professions at Drexel University. Her basic science [read more...]

Sweet Pee: Do SGLT2 Inhibitors Prevent and/or Slow the Progression of Diabetic Kidney Disease?

August 15, 2018 // 1 Comment

During NephMadness 2017, the newcomer ‘SGLT2 inhibitors’ team for the Diabetic Nephropathy region surprised the competition and made it all the way to the Filtered Four where it was knocked out by the eventual winner Genes in ESKD Disparity. In [read more...]

Creatinine Linearity – Connecting the Dots Has Never Been So Complicated

December 8, 2017 // 0 Comments

Prediction. My least favorite part of the chronic kidney disease (CKD) clinic visit. “No crystal ball.” “I’m not in a position to guess.” “Only God knows the answer to that.” These are all lines I have used to warn patients that my [read more...]

#NephMadness 2017: The Changing Nature of Diabetic Kidney Disease

March 28, 2017 // 0 Comments

NephMadness 2017 | @NephMadness | #NephMadness or #DNRegion Raymond C. Harris Dr. Harris, MD, is Director of the Division of Nephrology at Vanderbilt University Medical Center and Director of the Vanderbilt Center for Kidney Disease. The [read more...]

#NephMadness 2017: The Year of the Gs – GLP-1 Receptor Agonists and Gonzaga

March 21, 2017 // 1 Comment

Submit your picks! | NephMadness 2017 | #NephMadness or #DNRegion Katherine R. Tuttle Dr. Tuttle, MD, is Executive Director for Research at Providence Health Care in Spokane, Washington. She is Co-Principal Investigator of the Institute of [read more...]

#KidneyWk 2016: State of the Art Lectures

November 22, 2016 // 0 Comments

One of the major highlights of KidneyWk 2016 is the State of the Art Lectures, which are presented daily in the plenary session by a renowned scientist. These are topics of interest in the broader medical sense – and these experts provide a high [read more...]

#KidneyWk 2015: Not Just VEGF: Diabetes and the Endothelium

November 10, 2015 // 0 Comments

Diabetes and Diabetic Nephropathy (DN) were appropriately prominent topics at this year’s meeting. Thursday’s afternoon session, “Glomerular Endothelial Cell Injury in Diabetic Nephropathy” was an important reminder that endothelial injury [read more...]

Somatomedins and the Kidneys

September 18, 2014 // 0 Comments

Insulin-like growth factors (IGF) are a group of peptides that include insulin and relaxins with a common structural feature of three disulfide bonds linking a variable and a domain chain. Indeed, they were named for this reason, having been [read more...]

AJKD Blog

Official Blog of the American Journal of Kidney Diseases